MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.

威斯康星州麦迪逊市。-（商业新闻短讯）--灵巧治疗公司宣布丹·弗林和布莱恩·卡利已加入公司董事会。两者都带来了深刻的创业和药物开发记录，这将指导Nimble继续追求其内部渠道。

Dr. Flynn has over 40 years of experience in the discovery and development of high-impact medicines. He recently retired from Deciphera Pharmaceuticals, a company he founded in 2003. At Deciphera, Dr. Flynn held positions of Chief Executive Officer, Executive Vice President, and Chief Scientific Officer where he oversaw the progression of several molecules through clinical trials, including Qinlock® for the treatment of gastrointestinal stromal tumors.

弗林博士在发现和开发高影响力药物方面拥有40多年的经验。他最近从他于2003年创立的解密制药公司退休。在Deciphera，Flynn博士担任首席执行官、执行副总裁和首席科学官，通过临床试验监督几种分子的进展，包括用于治疗胃肠道间质瘤的Qinlock®。

Before founding Deciphera, Dr. Flynn held senior roles with various companies including Millennium Pharmaceuticals, Amgen Inc. and the Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence. He has served as the National Chair for the Division of Medicinal Chemistry of the American Chemical Society, is an American Chemical Society Fellow, and founder of the Bioorganic and Medicinal Chemistry Foundation.

在成立Deciphera之前，Flynn博士曾在多家公司担任高级职务，包括Millennium Pharmaceuticals，Amgen Inc.和Monsanto Company，G.D.Searle Unit。弗林博士目前是堪萨斯大学劳伦斯分校药物化学的兼职教授。

He is a member of the Board of Directors and Scientific Advisory Boards of several biotech companies. Dr. Flynn received both his B.S. in pharmacy and Ph.D. in medicinal chemistry from the University of Kansas and completed post-doctorate training in synthetic organic chemistry at Indiana University..

他是几家生物技术公司的董事会和科学顾问委员会的成员。Flynn博士在堪萨斯大学获得药学学士学位和药物化学博士学位，并在印第安纳大学完成了合成有机化学的博士后培训。。

Dr. Cali has over 25 years of pharma biotech experience. He co-founded Ironwood Pharmaceuticals in 1998 where he held leadership roles across R&D and corporate development and helped drive the company’s transformation from an early discovery stage startup to a commercial stage company with a market leading gastrointestinal (GI) disease product (Linzess®) and a diverse pre-commercial pipeline.

卡利博士拥有超过25年的制药生物技术经验。他于1998年共同创立了Ironwood Pharmaceuticals，在研发和企业发展方面担任领导角色，并帮助推动公司从早期发现阶段的初创公司转变为商业阶段的公司，拥有市场领先的胃肠道（GI）疾病产品（Linzess®）和多样化的商业前管道。

Brian also led the investor engagement and financing efforts that enabled the creation of Cyclerion, an Ironwood spinout, in 2019. He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018. He holds a B.S. from Cornell University, a Ph.D. in Cell and Molecular Biology from the University of Wisconsin-Madison and was a postdoctoral fellow at the Whitehead Institute..

Brian还领导了投资者参与和融资工作，从而在2019年创建了铁木衍生产品Cyclerion。他目前担任Jnana Therapeutics的董事会成员，自2018年以来一直担任该职位。他拥有康奈尔大学的学士学位，威斯康星大学麦迪逊分校的细胞和分子生物学博士学位，并且是怀特黑德研究所的博士后研究员。。

'We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution,' said Jigar Patel, founder & CEO of Nimble Therapeutics. 'Both are renowned pharma biotech entrepreneurs, having founded and successfully led companies that have developed novel small molecule or peptide-based drugs.

Nimble Therapeutics创始人兼首席执行官吉加·帕特尔（JigarPatel）说，在Nimble发展的这一重要阶段，我们很高兴欢迎丹尼尔（Daniel）和布莱恩（Brian）加入我们的董事会他们都是著名的制药生物技术企业家，创立并成功领导了开发新型小分子或肽基药物的公司。

We look forward to their guidance as we work to bring breakthrough medicines into clinical development, and ultimately to patients in need.”.

我们期待着他们的指导，因为我们正在努力将突破性药物带入临床开发，并最终惠及有需要的患者。”。

'Daniel and Brian are valuable additions to Nimble’s board, and their expert guidance will be paramount to the company as it continues to concentrate on developing and progressing its internal pipeline,” said Board Chair Dan Zabrowski.

董事会主席丹·扎布罗夫斯基（DanZabrowski）表示：“丹尼尔（Daniel）和布莱恩（Brian）是敏捷董事会的宝贵补充，他们的专家指导对公司至关重要，因为公司将继续专注于开发和推进内部渠道。”。

“It is an exciting time to be joining Nimble as they seek to leverage their incredibly versatile technology and team to develop best-in-class / first-in-class peptide-based medicines for the treatment of important diseases.” said Dr. Flynn.

Flynn博士说：“加入Nimble是一个激动人心的时刻，因为他们寻求利用其难以置信的多功能技术和团队来开发一流/一流的肽基药物，用于治疗重要疾病。”。

“Nimble has a paradigm shifting platform and I am impressed with what they have already accomplished. I look forward to helping the company as their efforts toward their own pipeline intensify, and they push towards the clinic and beyond.” said Dr. Cali.

卡利博士说：“敏捷拥有一个范式转换平台，他们已经取得的成就给我留下了深刻的印象。我期待着帮助该公司加强对自己管道的努力，并将其推向诊所和其他领域。”。

About Nimble Therapeutics

关于敏捷疗法

Nimble is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods.

Nimble是一家生物技术公司，致力于实现肽疗法的承诺。利用一个范式转换的肽药物发现和开发引擎，Nimble正在推进其内部管道，并继续支持几个合作项目。灵活的平台结合了大规模并行固相合成，无与伦比的化学和结构多样性，复杂的测定以及强大的机器学习和计算方法。

Nimble is located in Madison, WI and Philadelphia, PA. For more information, visit www.nimbletherapeutics.com..

Nimble位于威斯康星州麦迪逊和宾夕法尼亚州费城。有关更多信息，请访问www.nimbletherapeutics.com。。